Targacept
Founded Year
1997Stage
IPO | IPOTotal Raised
$123.49MDate of IPO
4/13/2006Market Cap
0.01BStock Price
0.29About Targacept
Targacept is a biopharmaceutical company advancing NNR Therapeutics for the treatment of various diseases and disorders. The company's NNR Therapeutics selectively target neuronal nicotinic receptors, or NNRs. NNRs are found on nerve cells throughout the nervous system and serve as key regulators of nervous system activity.
Missing: Targacept's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Targacept's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Expert Collections containing Targacept
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Targacept is included in 1 Expert Collection, including Biopharma Tech.
Biopharma Tech
15,535 items
Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.
Targacept Patents
Targacept has filed 62 patents.

Application Date | Grant Date | Title | Related Topics | Status |
---|---|---|---|---|
3/12/2014 | 3/14/2017 | Amines, Piperidines, Psychiatric diagnosis, Fluoroarenes, Stimulants | Grant |
Application Date | 3/12/2014 |
---|---|
Grant Date | 3/14/2017 |
Title | |
Related Topics | Amines, Piperidines, Psychiatric diagnosis, Fluoroarenes, Stimulants |
Status | Grant |
Latest Targacept News
Feb 6, 2020
Omega-backed startup sells itself quietly; AbbVie breaks out more Rinvoq data; Revance gets FDA date for Botox rival → When it came into the limelight with a $35 million Series A financing in 2018 , Attenua promised to repurpose three oral neuronal nicotinic receptor assets discarded by Catalyst Biosciences (which in turn got the drugs through a merger with Targacept). But now that it’s wrapped a proof-of-concept trial of the lead drug in chronic cough, Attenua is flipping the portfolio to another buyer for yet another use. CODA Biotherapeutics has bought Attenua and its clinical stage small molecule candidates, which they say will serve to control their chemogenetic receptors designed to treat neuropathic pain, focal epilepsy and other neurologic disorders. The South San Francisco biotech liked that Attenua’s drugs come with “high-quality drug development work already completed, one with a currently active IND,” CEO Michael Narachi said. According to clinicaltrials.gov Attenua completed its chronic cough study in May last year, where it compared bradanicline to placebo, but has not posted the results publicly. Omega Funds, Abingworth, OrbiMed and Redmile Group invested in Attenua. The financial terms of the buyout deal were not disclosed. → AbbVie’s oral JAK inhibitor Rinvoq, which is partly expected to fill the giant Humira hole after the megablockbuster falls off its patent cliff, has more positive data backing its use. The company on Wednesday issued data from a pivotal study in psoriatic arthritis patients, months after publishing similarly positive results from another Phase III trial in the same patient population. Rinvoq was approved by the FDA in August for use in patients with rheumatoid arthritis, although the label came with the dreaded black box warning that have plagued the class of drugs. → Co-founder Dan Browne may have stepped down in October following a “ misjudgment in handling an employee matter ,” but California-based Revance is going full steam ahead with its Botox rival DaxibotulinumtoxinA for Injection (DAXI). The product has been accepted for review by the FDA for use in frown lines, and the agency is expected to make its decision by November 25. DAXI is positioned as a direct competitor to Allergan’s Botox franchise — a product that is approved for 13 indications and generated close to $3.6 billion in 2018, despite the emergence of rivals: Ipsen’s Dysport and Merz Pharma’s Xeomin. Another competitor, Evolus, scored FDA approval for its product, Jeuveau, in February 2019. → Italy’s Chiesi, which has allied with Israeli biotech Protalix to develop an enzyme replacement therapy for Fabry disease, is now carving out a whole new division to focus on rare and ultra-rare diseases . It will be headquartered in Boston and conduct R&D in lysosomal storage disorders, as well as rare hematology and ophthalmology diseases. → Tiny Tonix, whose experimental PTSD drug Tonmya lost its breakthrough therapy status, ceased enrollment of a pivotal study on Wednesday after an independent monitoring panel recommended stopping the trial due to futility on the basis that the drug likely does not work. Beset with multiple setbacks, Tonix has done everything in its power to get Tonmya across the finish line, including changing trial goalposts and using subset analyses to take the program forward. The drug will continue to be tested in patients with fibromyalgia. → The Chinese tech giant Tencent managed to rivet attention its way when the company temporarily posted an update on the coronavirus epidemic that listed close to 25,000 deaths and more than 154,000 cases in China. The official number of deaths is a bit more than 500. The conglomerate quickly reverted to the official numbers once the report had been flagged by alarmed observers. Taiwan News reported that the company may have inadvertently revealed the actual figures being tracked, as opposed to the numbers China prefers. Either way, the report underscores some lingering doubts that the Chinese government is not being completely upfront about the way it’s handled the brewing pandemic so far. The government has about 60 million citizens under lockdown to try and help contain the spread of the Wuhan virus, which has severely disrupted the country’s economy. → Following up on some promising mid-stage data out of ESMO, Curis has convinced its partners at Aurigene to fund and conduct a Phase IIb/III study of CA-170 among patients with non-squamous non-small cell lung cancer (nsNSCLC). In exchange Aurigene, a subsidiary of India’s Dr. Reddy’s Labs, gets the rights to develop and commercialize the drug in all of Asia — adding to an existing agreement for India and Russia. Designed to be used in combination with chemoradiation, CA-170 is an oral drug that inhibits both PD-L1 and VISTA. Author UPDATED: GlaxoSmithKline's latest makeover includes auctioning off dermatology, adding new tech and layoffs. But how many? GSK execs announced Wednesday morning that they are setting up a 2-year program to prepare the company for its split in two — consumer healthcare and the R&D-focused outfit she and research chief Hal Barron promised to revamp and reenergize 2 years ago. A key part of that effort is a new R&D reorganization in which the vaccines group — traditionally separate inside the global organization — will integrate its work with the pharma teams in order to orchestrate common research themes on both sides. And GSK is helping pay for the 2-year program with a plan to sell off non-core assets, starting with its dermatology drugs portfolio. Keep reading Endpoints with a free subscription Unlock this story instantly and join 71,400+ biopharma pros reading Endpoints daily — and it's free. SUBSCRIBE Jeffrey Bluestone exits Parker and switches focus back to autoimmune diseases in cell therapy 2.0 launch Jeffrey Bluestone is returning to the scientific field where he forged his reputation as a drug hunter and top investigator. The prominent scientist has handed in his walking papers as CEO of the high profile Parker Institute for Cancer Immunotherapy, switched to the adjunct faculty at UCSF and is now launching a new company, where he plans to take a hands-on role in the development of new cell therapies for autoimmune and degenerative diseases. Keep reading Endpoints with a free subscription Unlock this story instantly and join 71,400+ biopharma pros reading Endpoints daily — and it's free. SUBSCRIBE Ian Read adds a new post to his growing roster of post-Pfizer positions — and this one pays well Ian Read may have to pick up the pace a bit to meet the swelling number of jobs he’s added to his resume since recently retiring from Pfizer after a 41-year run that included 9 years at the top. Today we learned that Read is taking the chairman’s spot on the board of tech player DXC, a data management outfit that has a big focus on healthcare and the life sciences industry. Read is being well paid for his time and attention. Their SEC filing notes that the ex-Pfizer CEO and chairman will earn an annual retainer of $450,000 in stock, pro-rated to his March 16 start date. Read More Roche/PTC edge closer to disrupting market for SMA rivals Biogen and Novartis with more positive data Roche and partner PTC Therapeutics have broken out detailed positive data backing their spinal muscular atrophy therapy, which is expected to have a good shot at eclipsing Spinraza’s market leadership. The FDA is set to make its decision on the therapy, risdiplam, by May 24. If approved — the drug is expected to generate between $2 billion and $3 billion in peak sales — and compete with Biogen’s first-to-market Spinraza and Novartis’ most-expensive-drug-in-the-world Zolgensma. Read More Party on: Base editing startup, computational drug discovery experts and CRO bag close to $2B total on their way to Nasdaq On the back of Black Diamond Therapeutics’ roaring public debut, the IPO momentum is pushing three biotech players from very different corners of the industry to shiny listings on the Nasdaq. Gene editing startup Beam Therapeutics, computational drug discovery specialist Schrödinger and contract research organization PPD have collectively bagged close to $2 billion by pricing at the top of or above the range laid out in their terms. CRISPR trailblazers raise $180M for the next big thing in gene editing Keep reading Endpoints with a free subscription Unlock this story instantly and join 71,400+ biopharma pros reading Endpoints daily — and it's free. SUBSCRIBE
Targacept Frequently Asked Questions (FAQ)
When was Targacept founded?
Targacept was founded in 1997.
Where is Targacept's headquarters?
Targacept's headquarters is located at 100 North Main Street, Winston-Salem.
What is Targacept's latest funding round?
Targacept's latest funding round is IPO.
How much did Targacept raise?
Targacept raised a total of $123.49M.
Who are the investors of Targacept?
Investors of Targacept include Aventis Venture Activities, SG Asset Management, Innovation Capital, SR One, Burrill & Company and 17 more.
Who are Targacept's competitors?
Competitors of Targacept include Arena Pharmaceuticals, Evotec SE, Integral Molecular, Relypsa, Catabasis Pharmaceuticals and 13 more.
Compare Targacept to Competitors
Humanetics is a clinical-stage pharmaceutical company engaged in developing and commercializing products to enhance human health and wellbeing in markets with urgent and unmet needs. It has a focus on radiation modulators for oncology, medical imaging, and medical countermeasure uses. The company develops BIO 300, a highly selective modulator of inflammation, cell cycle arrest, and DNA damage repair. Humanetics was founded in 1988 and is based in Minneapolis, Minnesota.
AnaMar Medical is a company in the field of cartilage biology and associated joint diseases. The company has an project portfolio with five drugs and one biomarker in development and two biomarkers on the market.
Xytis is engaged in the development of central nervous systems drugs.
The company is engaged in developing and commercializing drugs for the hospital-based treatment of central nervous system (CNS) disorders and thrombotic/cardiovascular diseases, indications for which there is a substantial unmet medical need.
Mimetogen is actively pursuing the development of novel small molecule compounds to treat neurodegenerative diseases of the eye, including dry eye, glaucoma and retinitis pigmentosa. The company designs and develops small molecule drugs that mimic the effects of neurotrophins, proteins that help maintain the health and growth of many cells and tissues found in the eye. Making drugs that can mimic the large natural molecules may lead to the development of novel approaches to treat degenerative ocular diseases such as glaucoma, retinitis pigmentosa, age-related macular degeneration and dry eye.
Richwood develops drugs for disorders of the central nervous system, particularly hyperactivity in children.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.